CAS 857086-93-2

(1S,2R)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(methylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol

CAS: 857086-93-2

Formula: C₃₂H₃₁BrN₂O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 555.5047

Ref: IN-DA00G3QK

(1S,2R)-Bedaquiline

CAS: 857086-93-2

(1S,2R)-Bedaquiline

Purity: 98%

Molecular weight: 555.5g/mol

Ref: 54-OR1033208

(1S,2R)-1-(6-BROMO-2-METHOXYQUINOLIN-3-YL)-4-(DIMETHYLAMINO)-2-(NAPHTHALEN-1-YL)-1-PHENYLBUTAN-2-OL

CAS: 857086-93-2

Purity: 98%

Color and Shape: Solid

Molecular weight: 555.5159912109375

Ref: 10-F824432

(AlphaR,BetaS)-Bedaquiline

Controlled Product

CAS: 857086-93-2

Applications (αR,βS)-Bedaquiline is an intermediate in the synthesis of (αS,βR)-Bedaquiline (B119540), which is a diarylquinoline derivative that acts as a mycobacterial inhibitor. Bedaquiline shows promise as potential drug in the treatment of tuberculosis.
References Cheepsattayakorn, A., et al.: Anti-Infect. Drug. Discover.,7, 141 (2012); de Jonge M.R. et al.: Proteins, 67, 971 (2007); Diacon A.H. et al.: N. Eng. J. Med., 360, 2397 (2009);

Formula: C₃₂H₃₁BrN₂O₂

Color and Shape: Neat

Molecular weight: 555.5

Ref: TR-B119535

(±R,²S)-Bedaquiline

CAS: 857086-93-2

(±R,²S)-Bedaquiline is a diarylquinoline that is used in the treatment of drug-resistant tuberculosis. It has shown efficacy against multidrug-resistant tuberculosis and has been shown to reverse abnormal changes in bacterial DNA induced by injury. Bedaquiline displays antimycobacterial activity and is typically used as part of a multidrug regimen for the treatment of tuberculosis. Clinical trials have demonstrated that bedaquiline can improve pulmonary function, reduce the risk of decline in lung function, and improve survival rates for patients with drug-resistant tuberculosis.

Formula: C₃₂H₃₁BrN₂O₂

Purity: Min. 95%

Molecular weight: 555.5 g/mol

Ref: 3D-HJB08693